APA (7th ed.) Citation

CS, H., LM, R., C, H., W, F., S, S., A, H., . . . JM, H. (2022). Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity. Annals of surgical oncology, 29(4), 2456. https://doi.org/10.1245/s10434-021-11202-8

Chicago Style (17th ed.) Citation

CS, Hill, et al. "Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity." Annals of Surgical Oncology 29, no. 4 (2022): 2456. https://doi.org/10.1245/s10434-021-11202-8.

MLA (9th ed.) Citation

CS, Hill, et al. "Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity." Annals of Surgical Oncology, vol. 29, no. 4, 2022, p. 2456, https://doi.org/10.1245/s10434-021-11202-8.